This Medudy course is a video tutorial for physicians on the topic of "Berberine ursodeoxycholic acid in type 2 diabetes". The format used here is a so-called "Journal Club Summary", in which we summarize the latest and most clinically relevant studies for you.
Berberine ursodeoxycholate or HTD1801 is a novel oral metabolic modulator with a dual mechanism of action. By activating adenosine monophosphate kinase and simultaneously inhibiting the NLRP3 inflammasome, it is thought to improve glucose and lipid metabolism, thereby reducing inflammation and improving insulin resistance. Therefore, today's study investigated the safety and efficacy of berberine ursodeoxycholate in patients with type 2 diabetes and inadequate control by diet and exercise.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
At the end of this course you will know
- the clinical background and relevance of the research question under investigation
- the study design and methodology of the publication to answer the research question
- the results and key takeaways of the publication
- the conclusion of the publication and possible limitations
